Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T14:47:19.016Z.
Calculation as of: 2026-10-06T14:47:19.016Z.
Quote observation: 2026-10-06T14:45:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a840c676881d241076febf00b391d6b63dc7604cd07ac1d060a0848db02ea459
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Inhibikase Therapeutics, Inc.
Market Cap
$258.47M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$259.01M
Free Cash Flow Yield
N/A
TTM Avg
21.58%
3Y Avg
20.83%
5Y Avg
20.83%
Market Cap
$259.30M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$256.28M
Free Cash Flow Yield
0.22%
TTM Avg
0.70%
3Y Avg
0.62%
5Y Avg
0.64%
Market Cap
$260.33M
Free Cash Flow Yield
N/A
TTM Avg
2.40%
3Y Avg
2.40%
5Y Avg
2.40%
Market Cap
$254.52M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$250.48M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.27M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$272.91M
Free Cash Flow Yield
N/A
TTM Avg
41.16%
3Y Avg
41.16%
5Y Avg
41.16%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $258.47M | N/A | N/A | N/A | N/A |
| AC Immune S.A. (ACIU)vs › | $259.01M | N/A | 21.58% | 20.83% | 20.83% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | N/A | N/A | N/A | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.28M | 0.22% | 0.70% | 0.62% | 0.64% |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $260.33M | N/A | 2.40% | 2.40% | 2.40% |
| Century Therapeutics, Inc. (IPSC)vs › | $254.52M | N/A | N/A | N/A | N/A |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $250.48M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.27M | N/A | N/A | N/A | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | N/A | 41.16% | 41.16% | 41.16% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.95M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
